Dharmalingam, M., Aravind, S. R., Thacker, H., Paramesh, S., Mohan, B., Chawla, M., Asirvatham, A., Goyal, R., Shembalkar, J., Balamurugan, R., Kadam, P., Alva, H., Kodgule, R., Tandon, M., Vaidyanathan, S., Pendse, A., Gaikwad, R., Katare, S., Suryawanshi, S., & Barkate, H. (2020). Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial. Drugs, 80(6), 587–600. https://doi.org/10.1007/s40265-020-01285-0
Dobbins, R., Hussey, E. K., O'Connor-Semmes, R., Andrews, S., Tao, W., Wilkison, W. O., Cheatham, B., Sagar, K., & Hanmant, B. (2021). Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin. BMC pharmacology & toxicology, 22(1), 34. https://doi.org/10.1186/s40360-021-00502-0
Mohan, V., Mithal, A., Joshi, S. R., Aravind, S. R., & Chowdhury, S. (2020). Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy. Drug design, development and therapy, 14, 2487–2501. https://doi.org/10.2147/DDDT.S221093
Hussey, E. K., Kapur, A., O'Connor-Semmes, R., Tao, W., Rafferty, B., Polli, J. W., James, C. D., Jr, & Dobbins, R. L. (2013). Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC pharmacology & toxicology, 14, 25. https://doi.org/10.1186/2050-6511-14-25
Remogliflozin Etabonate: Uses, interactions, mechanism of action | DrugBank Online. (n.d.). DrugBank. https://go.drugbank.com/drugs/DB12935